Taylor & Francis Group
Browse
idrd_a_1639846_sm8440.docx (456.25 kB)

A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy

Download (456.25 kB)
journal contribution
posted on 2019-07-11, 11:42 authored by Yongmei Zhao, Gang Chen, Zhengjie Meng, Guangming Gong, Wei Zhao, Kaikai Wang, Tianqing Liu

Proteins such as albumin, gelatin, casein, transferrin, and collagen are widely used as drug delivery systems. However, only albumin-based paclitaxel (PTX) formulation Abraxane® (PTX-albumin NPs prepared by nab-technology) has been successfully developed for treating metastatic breast cancer clinically due to abundant materials, simple industrial scale-up process, and well tumor-targeting ability. Hemoglobin (Hb) is another protein used for drug delivery with similar advantages. In this study, we successfully synthesized PEG-Hb nanoparticles loading with PTX based on previously well-established acid-denatured method. PEG-Hb-PTX NPs showed enhanced cellular uptake and great cellular inhibition ability in vitro. Moreover, our animal study showed that PEGylated NPs greatly accumulated in tumor tissues and exhibited excellent anticancer activity in vivo. We found that PEG-Hb-PTX NPs possess a better in vivo antitumor effect than the commercially available Taxol® formulation. We believe that PEG-Hb has great potential as an efficient drug delivery system for further clinic study.

Funding

This work was supported by the China Postdoctoral Science Foundation (No. 2016M601923) and by the China National Science Foundation (No. 31671026). Dr Tianqing Liu is supported by the National Health and Medical Research Council (NHMRC) Early Career Fellowship (Grant No. 1112258).

History